English 
Neumarker and Cortica have formed a partnership to explore how artificial intelligence and brain activity data can help provide care for children with autism. This partnership was announced on October 15 2026. It will combine Neumarker’s large-scale EEG foundation model with Cortica’s deidentified clinical data and knowledge in neurodevelopmental care.
The partnership wants to find patterns in brain activity, called biomarkers that can help doctors understand why children react differently to the treatments. The goal in the run is to create better methods for predicting how treatment will work and to make care that fits each child’s needs.
This effort is still a research project. The announcement does not say that there are confirmed biomarkers or that the AI method can already predict treatment results in life.
Using AI With EEG and Clinical Data
Neumarker creates AI tools for treating conditions of the nervous system. Its system uses large-scale EEG foundation models and clinical information to look at brain activity and help with treatment choices.
EEG records activity in the brain using sensors on the head. Doctors and researchers use EEG in brain-related situations. Computer analysis can find patterns that’re hard to see with the naked eye.
In the partnership Neumarker will use its AI system and EEG modeling skills while Cortica will offer clinical knowledge and long-term patient data that has been made anonymous. By looking at these sources the two companies want to see if brain activity patterns match differences in patient situations and how they respond to treatments.
This method shows an interest, in using AI to study complex data and find signs that can help create more personalized health care. However any possible biomarker must be. Proven before it can be used to make medical decisions.
Addressing Differences in Autism Care
Autism covers a range of developmental traits and support needs. Children can have medical profiles and react differently to treatment options, which makes personalized evaluation a key part of care.
The companies want to look into whether clear biological signs can help explain some of this difference. If scientists find markers these could eventually give more information for checking how treatment works and choosing the right approaches.
Cortica provides a care model that is led by doctors for children with autism and other conditions that affect the system. Their services include help, applied behavior analysis (ABA) and care for development along with support for families and schools. The company also does research on results. Runs clinical trials through its Cortica Innovation Network.
The partnership combines this experience with Neumarker’s artificial intelligence skills. Of just using what doctors see researchers will look into whether brainwave patterns from EEG can give more understanding of how each child reacts to care.
The news does not say that the teamwork will take the place of medical evaluations or treatment methods. Any future use of AI findings would need to be checked with medical evidence and expert opinions.
Privacy and Research Validation Remain Important
The partnership will use data that has no details and follow all rules about patient privacy and research standards the companies said.
Using data that has no personal details is meant to stop people from being recognized in research data. So good management of data limits on who can see it and proper research control are still important when mixing health records with computer models.
Researchers must also check if any patterns they find are the same and important for use. AI systems can find links in sets of data but those links don’t automatically mean one thing causes another or that a prediction will work for a single patient.
More testing would be needed to see if any suggested signs work for groups of patients medical settings and treatment plans. The companies have not said when the research will be used in medical settings or given specific goals, for the study.
Extending AI Research in Neurodevelopmental Conditions
について Neumarker the partnership extends its AI platform into autism and other neurodevelopmental research. Its lead application, NMK-001 is in development for epilepsy according to the company.
こちらもお読みください： カルテコとGROOVE Xが業務提携を結んだ
For Cortica the collaboration adds another technology-focused research effort to its work on precision medicine and clinical outcomes. Combining clinical information with EEG analysis may help researchers explore connections between brain activity, patient characteristics and treatment response.
The broader significance will depend on whether the collaboration can move from analysis to reproducible findings that improve clinical understanding. The identification of biomarkers could eventually support more personalized decision-making but that potential remains to be demonstrated through research.
The partnership highlights a growing application of AI in healthcare: using models to analyse complex clinical and biological data in pursuit of more individualized care. For children, with autism and their families the practical value will ultimately depend on whether such research produces clinically useful evidence.
日本語